REVIEW

¹ Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna; Second Department of Medicine, Hietzing Hospital Vienna, Vienna, Austria
² Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, University of Toronto, Toronto, Canada
³ Leeds Teaching Hospitals Trust, Chapel Allerton Hospital, Leeds, UK
⁴ Arthritis Care, London, UK
⁵ Leiden University Medical School, Leiden, The Netherlands
⁶ Department of Rheumatology, Charité Hospital, Humboldt University, Berlin, Germany
⁷ Department of Rheumatology, Hopital Cochin, René Descartes University, Paris, France
⁸ Division of Rheumatology, Institute of Internal Medicine and Geriatrics, Catholic University of the Sacred Heart, Rome, Italy
⁹ Division of Haematology, First Department of Internal Medicine, Medical University of Vienna, Vienna, Austria
¹⁰ Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
¹¹ Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
¹² Rheumatology Department, Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain
¹³ Institute and Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic

Correspondence to:
Professor J S Smolen
Department of Rheumatology, Third Department of Internal Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; josef.smolen{at}wienkav.at

A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

Abbreviations: ACR, American College of Rheumatology; SCDAI, Simplified composite Disease Activity Index; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HACA, human antichimeric antibody; MTX, methotrexate; SDAI, simplified Disease Activity Index; TNF, tumour necrosis factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• KOUMAKIS, E., WIPFF, J., AVOUAC, J., KAHAN, A., ALLANORE, Y. (2009). Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-{alpha}-Blocking Agents. The Journal of Rheumatology 36: 2125-2126 [Full Text]  
• Ramos-Casals, M, Soto, M., Cuadrado, M., Khamashta, M. (2009). Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. Lupus 18: 767-776 [Abstract]  
• Ziswiler, H.-R., Aeberli, D., Villiger, P. M., Moller, B. (2009). High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis. Rheumatology (Oxford) 48: 939-943 [Abstract] [Full Text]  
• Blank, N., Max, R., Schiller, M., Briem, S., Lorenz, H.-M. (2009). Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Rheumatology (Oxford) 48: 440-441 [Full Text]  
• Bruce, S. P. (2009). Recent Developments in the Treatment of Rheumatoid Arthritis. Journal of Pharmacy Practice 22: 65-74 [Abstract]  
• Rieckmann, P., Traboulsee, A., Devonshire, V., Oger, J. (2008). Review: Escalating immunotherapy of multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 181-192 [Abstract]  
• Heemstra, K. A, Toes, R. E, Sepers, J., Pereira, A. M, Corssmit, E. P, Huizinga, T. W J, Romijn, J. A, Smit, J. W (2008). Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 159: 609-615 [Abstract] [Full Text]  
• Owczarczyk, K, Hellmann, M, Fliedner, G, Rohrs, T, Maizus, K, Passon, D, Hallek, M, Rubbert, A (2008). Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 67: 1648-1649 [Full Text]  
• (2008). Rituximab and {blacktriangledown}abatacept for rheumatoid arthritis. DTB 46: 57-61 [Abstract] [Full Text]  
• Thurlings, R M, Vos, K, Wijbrandts, C A, Zwinderman, A H, Gerlag, D M, Tak, P P (2008). Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67: 917-925 [Abstract] [Full Text]  
• Soriano, E. R., Galarza-Maldonado, C., Cardiel, M. H., Pons-Estel, B. A., Massardo, L., Caballero-Uribe, C. V., Achurra-Castillo, A. F., Barile-Fabris, L. A., Chavez-Corrales, J., Diaz-Coto, J. F., Esteva-Spinetti, M. H., Guibert-Toledano, M., Palazuelos, F. I., Keiserman, M. W., Lomonte, A. V., Mota, L. M. H., Pineda Villasenor, C., Alarcon, G. S., on behalf of GLADAR (Grupo Latino Americano de Est, (2008). Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology (Oxford) 47: 1097-1099 [Full Text]  
• Jung, N., Owczarczyk, K., Hellmann, M., Lehmann, C., Fatkenheuer, G., Hallek, M., Rubbert, A. (2008). Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology (Oxford) 47: 932-933 [Full Text]  
• Burr, M. L., Malaviya, A. P., Gaston, J. H., Carmichael, A. J., Ostor, A. J. K. (2008). Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology (Oxford) 47: 738-739 [Full Text]  
• Freidlin, J., Wong, I. G, Acharya, N. (2007). Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol 91: 1414-1414 [Full Text]  
• Ramos-Casals, M., Brito-Zeron, P. (2007). Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford) 46: 1389-1396 [Abstract] [Full Text]